Low dose lithium carbonate failed to delay progression of cognitive decline in patients with mild cognitive impairment (MCI) likely to progress to Alzheimer’s.
The results of this RCT were just published.
My note:
It’s very possible that they used the wrong form of lithium in this trial. We now know from Bruce Yankner’s recently published work at Harvard that it is the orotate form of lithium that has significant activity in Alzheimer’s models, not the carbonate form. Yankner predicted that the carbonate form would not work well. (Refer to comments section for more on this.)
See these previous posts on Yankner’s work:
↪ Harvard study ties lithium deficiency to Alzheimer's disease in mice and humans
↪ Human trials of lithium orotate for Alzheimer's to start spring 2026 at MGH/Brigham
↪ Harvard begins clinical trials of low-dose lithium for Alzheimer's



